Is Elevation Oncology Inc (NASDAQ: ELEV) No Longer A Good Investment?

After Hours

After-hours and pre-market trading may carry slightly higher risks than regular market hours. As issuers often announce important financial information outside regular trading hours, extended-hours trading may result in wider spreads for a particular security. That is because extended-hours trading may result in lower liquidity and higher volatility. Most recently, Yahoo Finance reported about the stock as it publicized that Elevation Oncology Announces Appointment of Darcy Mootz, Ph.D., to its Board of Directors.

#1 Small-Cap Uranium Stock for Ultra-Fast Gains in 2024

We've uncovered THE ONE small-cap uranium stock that has unearthed a near-surface, high-grade uranium discovery in the Saudi Arabia of Uranium — Canada's prolific Athabasca Basin. Best of all, this small-cap uranium stock is currently flying just below Wall Street's radar… giving you the early-entry opportunity around US$0.30 per share. But that won't last long. Drills are turning right now with results set to be released to the market very, very soon.

Learn all about it in this brand new FREE online report.
Sponsored

Stocks Info

ELEV belongs to the Healthcare sector of the NASDAQ while operating in the Biotechnology industry. At the end of the last regular session, the stock closed at $2.90 and fluctuated between $3.1700 as its day high and $2.8600 as its day low. The current market capitalization of Elevation Oncology Inc is $122.99M. A total of 1.45 million shares were traded on the day, compared to an average of 2.64M shares.

Investors also take into account insider trades in predicting how the stock will perform in the future. During the recent three months, ELEV has seen 0 BUY and 0 SELL insider trades, representing the acquisition of 0 and the disposition of 0 shares. Over the last 12 months, there were 3 BUYs and 4 SELLs from insiders. Insiders purchased 37,688 shares during that period but sold 30,096.

While price targets are rarely accurate, they tend to exert some kind of influence from time to time and are often taken into account by investors. According to analysts who have offered 12-month price targets for ELEV in the last 3 months, the mean price target is $4.83 with high estimates of $8.00 and low estimates of $1.50. In terms of 52-week highs and lows, ELEV has a high of $5.89 and a low of $0.36.

As of this writing, ELEV has an earnings estimate of -$0.23 per share for the current quarter. EPS was calculated based on a consensus of 4 estimates, with a high estimate of -$0.1 per share and a lower estimate of -$0.29. The company reported an EPS of -$0.37 in the last quarter, which was -15.60% lower than expectations of -$0.32.

Balance Sheet Annually/Quarterly

An organization’s balance sheet depicts the assets and liabilities it has, as well as the amount of equity invested. Investors can measure a company’s prospects by calculating its financial ratios using this information. ELEV’s latest balance sheet shows that the firm has $146.28M in Cash & Short Term Investments as of fiscal 2021. Its Book Value Per Share was $1.47, while its Total Shareholder’s Equity was $140.70M.

Analysts Opinion

There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for ELEV is Buy with a score of 5.00.

Most Popular

Related Posts